The PHARMO Institute, part of Lumanity, delivers research insights into immunoglobulin A nephropathy (IgAN).
Our data enables identification of a ‘gold standard’ pathologically-confirmed cohort of IgAN patients well-suited/ready for conducting research:
-
- ~2,700 patients with pathologically confirmed IgAN identifiable within the Pathology Registry
-
- ~650 patients with data from out-patient pharmacy and hospital data
-
- Unique linkages to clinical labs and pathology data to uncover specific blood and urine-based results and gain an in-depth understanding of disease progression and patient outcomes.
-
- Ability to address a wide range of RWE use cases from patient characteristics and subtyping, burden of illness and healthcare resource use, disease progression and outcomes, and beyond
E-mail us at contact@lumanity.com to discuss your research needs.
Download our IgAN one-pager
"*" indicates required fields
